Picture of RXO logo

RXO — RXO News Story

0.000.00%
us flag iconLast trade - 00:00
IndustrialsAdventurousLarge CapNeutral

Logistics firm RXO Q3 revenue misses analyst expectations on weak full-truckload market

Overview

RXO Q3 revenue of $1.42 bln missed analyst expectations

Adjusted EPS for Q3 was $0.01, missing analyst estimates

Brokerage volume grew 1% yr/yr, driven by 43% LTL volume growth

Outlook

RXO expects Q4 adjusted EBITDA between $20 mln and $30 mln

Company anticipates brokerage volume to decline by low-single-digit percentage in Q4

RXO forecasts Q4 brokerage gross margin between 12% and 13%

Result Drivers

LTL VOLUME GROWTH - Less-than-truckload volume increased by 43% year-over-year, driving brokerage volume growth

MARKET TIGHTNESS - Full-truckload market tightened due to capacity exits, impacting buy rates and brokerage gross margin

COST INITIATIVES - New cost initiatives expected to yield more than $30 mln of incremental savings

Key Details

MetricBeat/MissActualConsensus Estimate
Q3 RevenueMiss$1.42 bln$1.45 bln (15 Analysts)
Q3 Adjusted EPSMiss$0.01$0.05 (18 Analysts)
Q3 EPS-$0.08
Q3 Adjusted Net Income$2 mln
Q3 Adjusted EBITDA$32 mln
Q3 Adjusted EBITDA Margin2.30%
Analyst Coverage The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 15 "hold" and 3 "sell" or "strong sell" The average consensus recommendation for the ground freight & logistics peer group is "buy." Wall Street's median 12-month price target for RXO Inc is $17.00, about 3.6% below its November 5 closing price of $17.62 The stock recently traded at 55 times the next 12-month earnings vs. a P/E of 49 three months ago Press Release: ID:nBw7dYXqGa For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on RXO

See all news